Synergistic Suppression of Choroidal Neovascularization by Cavtratin and Aflibercept via Inhibition of the eNOS Pathway
Cavtratin combined with Aflibercept can effectively enhance anti-angiogenic efficacy and reduce inflammatory responses. Targeting the Cav-1/eNOS axis with Cavtratin provides a novel strategy to complement the limitations of anti-VEGF therapy. The synergistic effects of Cavtratin and Aflibercept suggest a promising approach to overcoming treatment resistance and improving clinical outcomes in CNV management.
Authors
- Hua Zuo (ORCID: https://orcid.org/0000-0002-8461-8988)
- Shasha Yang (ORCID: https://orcid.org/0000-0002-6646-5332)
- Yue Dong (ORCID: https://orcid.org/0000-0002-8516-6389)
- Chengguo Zuo (ORCID: https://orcid.org/0000-0003-0194-3345)
- Yanlin Li (ORCID: https://orcid.org/0000-0002-4234-5539)
- Wei Huang (ORCID: https://orcid.org/0000-0002-7606-345X)
- Hui‐Shan Lin (ORCID: https://orcid.org/0000-0003-4863-6174)
- Kun Wei
- Xuan Zhou (ORCID: https://orcid.org/0000-0001-5750-1728)
- Jingwei Yao
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Guangzhou First People's Hospital (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Current Eye Research
- Published
- 2025-08-03
- DOI
- https://doi.org/10.1080/02713683.2025.2523916
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province